☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
eccogene
Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from A...
October 23, 2024
Eccogene Enters into a Collaboration Agreement with AstraZeneca to Develop and Commercialize ECC5004 for Cardiometabolic Diseases
November 9, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.